Farmasintez-Nord

History

2023: The launch of the production of General Ministers in St. Petersburg

In early September 2023, Pharmasintez-Nord launched the production of three types of recombinant human insulins (general insulins). A little later, the company plans to start working with analog drugs.

According to the general director of the enterprise Mikhail Kvasnikov, the capacity of the plant for their production is more than 5 million units of products per year.

Pharmasintez-Nord has launched the production of three types of general ulins

Currently, the company's portfolio includes not only human genetically engineered insulin drugs, but also analogues - insulin glargine and insulin lispro, "he said in early September 2023 (quoted by Kommersant).

According to the general director of the plant, it is also planned to export products. At the moment, potential needs for drugs have already been identified in several countries, but it is too early to talk about expanded supplies, since the registration process abroad takes some time, the company noted.

Investments in the launch of production amounted to 1.7 billion rubles. The company will be able to occupy from 5% to 10% of the Russian insulin market.

Pavel Rasshchupkin, director of analytics at ARENCY Pharma, in a conversation with the publication, noted that, given the presence of fairly strong local players on the market - Pharmstandard and Geropharm, the competition will be quite difficult. Pharmasintez-Nord will be able to count on significant market shares in the event of a successful price offer. "Specific figures are quite difficult to predict, but they can fluctuate within 5-10% in the first years," Rasshchupkin argues.

The situation with insulin in pharmacies is stable, all the main players continue to supply to the Russian market, we do not record any interruptions. A significant part of the market falls on the state segment, which is equally distributed in packages between Russian and foreign companies. The launch of production at Pharmasintez-Nord will make domestic insulin more affordable for patients both in the pharmacy market and in the public procurement segment, he added.[1]

Notes